Article
First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
Cancer science - 1 Dec 2016
Chen Yongshun, Yang Jing, Li Xue, Hao Daxuan, Wu Xiaoyuan, Yang Yuanyuan, He Chunyu, Wang Wen, Wang Jianhua
Abstract excerpt
We proposed to compare the outcomes of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone with EGFR-TKI plus whole-brain radiotherapy (WBRT) for the treatment of brain metastases (BM) in patients with EGFR-mutated lung adenocarcinoma. A total of 1665 patients were screened from 2008 to 2014, and 132 were enrolled in our study. Among the 132 patients, 72 (54.5%) harbored a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.